<code id='374401130D'></code><style id='374401130D'></style>
    • <acronym id='374401130D'></acronym>
      <center id='374401130D'><center id='374401130D'><tfoot id='374401130D'></tfoot></center><abbr id='374401130D'><dir id='374401130D'><tfoot id='374401130D'></tfoot><noframes id='374401130D'>

    • <optgroup id='374401130D'><strike id='374401130D'><sup id='374401130D'></sup></strike><code id='374401130D'></code></optgroup>
        1. <b id='374401130D'><label id='374401130D'><select id='374401130D'><dt id='374401130D'><span id='374401130D'></span></dt></select></label></b><u id='374401130D'></u>
          <i id='374401130D'><strike id='374401130D'><tt id='374401130D'><pre id='374401130D'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:26
          Monica Bertagnolli -- health policy coverage from STAT
          NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

          WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

          “It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

          advertisement

          But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          A daunting task: navigating dual Medicare, Medicaid eligibility
          A daunting task: navigating dual Medicare, Medicaid eligibility

          AdobeThreemonthsago,myauntMargarethadastroke.Daysbefore,shewasrepaintingherbathroomanddrivingherself

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          AstraZeneca bets AAV gene therapy will still deliver the goods

          AlastairGrant/APSengChenghasbeenworkingingenetherapyfornearlyaslongasgenetherapyhasbeenafield.Asayou